<DOC>
	<DOC>NCT00968422</DOC>
	<brief_summary>The objectives of this study are to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ABT-384 in elderly subjects.</brief_summary>
	<brief_title>A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects</brief_title>
	<detailed_description />
	<criteria>1. Age is 65 years or greater 2. Judged to be in a condition of general good health based on the results of medical history, physical examination, vital signs, laboratory profile and a 12lead ECG 1. Use of protocolprohibited medications within 2 weeks prior to study drug administration. 2. Positive urine drug screen for nonprescribed drugs of abuse including alcohol. 3. Receipt of any drug depot by injection within 30 days prior to study drug administration. 4. Receipt of any investigational product within 6 weeks prior to study drug administration. 5. History of significant sensitivity or allergy to any drug. 6. History of drug or alcohol abuse within 2 years. 7. Positive test result for HBV, HCV or HIV. 8. Estimated creatinine clearance &lt; 30 mL/min. 9. Donation or loss of 5 mL/kg or more blood volume or receipt of any blood product within 8 weeks prior to study drug administration. 10. Current enrollment in another clinical study.</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Pharmacology</keyword>
	<keyword>Drug Safety</keyword>
	<keyword>Phase 1 Clinical Trials</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>